Search

Your search keyword '"Møller, Michael B"' showing total 385 results
Start Over Author "Møller, Michael B"
385 results on '"Møller, Michael B"'

51. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.

Author

Hua You, Xu-Monette, Zijun Y., Li Wei, Nunns, Harry, Nagy, Máté L., Bhagat, Govind, Xiaosheng Fang, Feng Zhu, Visco, Carlo, Tzankov, Alexandar, Dybkaer, Karen, Chiu, April, Tam, Wayne, Youli Zu, Hsi, Eric D., Hagemeister, Fredrick B., Jooryung Huh, Ponzoni, Maurilio, Ferreri, Andrés J. M., and Møller, Michael B.

Subjects
DIFFUSE large B-cell lymphomas, SINGLE nucleotide polymorphisms, EPIGENETICS, IMMUNE checkpoint inhibitors, GENETIC mutation
Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma with high mutation burdens but a low response rate to immune checkpoint inhibitors. In this study, we performed targeted next-generation sequencing and fluorescent multiplex immunohistochemistry, and investigated the clinical significance and immunological effect of mutation numbers in 424 DLBCL patients treated with standard immunochemotherapy. We found that KMT2D and TP53 nonsynonymous mutations (MUT) were significantly associated with increased nonsynonymous mutation numbers, and that high mutation numbers (MUThigh) were associated with significantly poorer clinical outcome in germinal center B-cell-like DLBCL with wild-type TP53. To understand the underlying mechanisms, we identified a gene-expression profiling signature and the association of MUThigh with decreased T cells in DLBCL patients with wild-type TP53. On the other hand, in overall cohort, MUThigh was associated with lower PD-1 expression in T cells and PD-L1 expression in macrophages, suggesting a positive role of MUThigh in immune responses. Analysis in a whole-exome sequencing dataset of 304 patients deposited by Chapuy et al. validated the correlation of MUT-KMT2D with genomic complexity and the significantly poorer survival associated with higher numbers of genomic single nucleotide variants in activated B-cell-like DLBCL with wild-type TP53. Together, these results suggest that KMT2D inactivation or epigenetic dysregulation has a role in driving DLBCL genomic instability, and that genomic complexity has adverse impact on clinical outcome in DLBCL patients with wild-type TP53 treated with standard immunochemotherapy. The oncoimmune data in this study have important implications for biomarker and therapeutic studies in DLBCL. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

55. <html>Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma</html>

Author

Orazi, Attilio, Ponzoni, Maurilio, Richards, Kristy L., Ferreri, Andrés J.M., Winter, Jane N., Tzankov, Alexandar, van Krieken, J. Han, Parsons, Ben M., Deng, Lijuan, Manyam, Ganiraju C., Choi, William W.L., Montes-Moreno, Santiago, Zhang, Li, Young, Ken H., Visco, Carlo, Møller, Michael B., Wang, Xiaoxiao, Piris, Miguel A., Hu, van den Shimin, Zu, Youli, Hsi, Eric D., Chiu, April, Bhagat, Govind, Xu-Monette, Zijun Y., Dybkær, Karen, Huh, Jooryung, Ye, Qing, and Medeiros, L. Jeffrey

Subjects
immune system diseases, hemic and lymphatic diseases
Abstract

Double-hit B-cell lymphoma is a common designation for a group of tumors characterized by concurrent translocations of MYC and BCL2, BCL6, or other genes. The prognosis of concurrent MYC and BCL6 translocations is not well known. In this study, we assessed rearrangements and expression of MYC, BCL2 and BCL6 in 898 patients with de novo diffuse large B-cell lymphoma treated with standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab). Neither BCL6 translocation alone (more frequent in activated B-cell like diffuse large B-cell lymphoma) nor in combination with MYC translocation (observed in 2.0% of diffuse large B-cell lymphoma) predicted poorer survival in diffuse large B-cell lymphoma patients. Diffuse large B-cell lymphoma patients with MYC/BCL6 co-expression did have significantly poorer survival, however, MYC/BCL6 co-expression had no effect on prognosis in the absence of MYC/BCL2 co-expression, and had no additive impact in MYC+/BCL2+ cases. The isolated MYC+/BCL6+/BCL2− subset, more frequent in germinal center B-cell like diffuse large B-cell lymphoma, had significantly better survival compared with the isolated MYC+/BCL2+/BCL6− subset (more frequent in activated B-cell like diffuse large B-cell lymphoma). In summary, diffuse large B-cell lymphoma patients with either MYC/BCL6 rearrangements or MYC/BCL6 co-expression did not always have poorer prognosis; MYC expression levels should be evaluated simultaneously; and double-hit B-cell lymphoma needs to be refined based on the specific genetic abnormalities present in these tumors.

Published
2016
Full Text
View/download PDF

56. Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations

Author

Visco, Carlo, primary, Wang, Jinfen, additional, Tisi, Maria Chiara, additional, Deng, Lijuan, additional, D'Amore, Emanuele S G, additional, Tzankov, Alexandar, additional, Montes-Moreno, Santiago, additional, Dybkær, Karen, additional, Bhagat, Govind, additional, Hsi, Eric D, additional, van Krieken, J Han, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J M, additional, Møller, Michael B, additional, Piris, Miguel A, additional, Medeiros, L Jeffrey, additional, Xu-Monette, Zijun Y, additional, and Young, Ken H, additional

Published
2017
Full Text
View/download PDF

58. High intratumoural galectin-1 expression predicts adverse outcome in ALK- ALCL and CD30+ PTCL-NOS.

Author

Holst, Johanne Marie, Ludvigsen, Maja, Hamilton‐Dutoit, Stephen Jacques, Bendix, Knud, Plesner, Trine Lindhardt, Nørgaard, Peter, Møller, Michael B., Steiniche, Torben, Rabinovich, Gabriel A., d'Amore, Francesco, Pedersen, Martin Bjerregård, and Hamilton-Dutoit, Stephen Jacques

Subjects
CYTOTOXIC T cells, LACTATE dehydrogenase
Abstract

Galectin-1 (Gal-1) has been associated with adverse prognosis in several cancers including lymphoma entities with CD30 expression. However, Gal-1 expression has not been systematically assessed in peripheral T-cell lymphomas (PTCL). Specimens from 169 nodal PTCL were assessed for intratumoural Gal-1 expression by immunohistochemistry. Overall survival (OS) in groups exhibiting high and low Gal-1 expression was compared in the cohort and in a subset analysis of CD30-positive PTCL only. Gal-1 expression was also correlated with biomarkers of the tumour microenvironment. No significant difference in OS based on Gal-1 expression was observed in the entire PTCL cohort. However, in the CD30-positive cohort, patients with high Gal-1 levels had significantly poorer outcome (5 years OS 10%, 95% confidence interval CI, 1-36) than their low Gal-1 counterparts (5 years OS 48%, 95% CI, 30-64, P = .021). In univariate analyses age 60 or younger, non-elevated lactate dehydrogenase (LDH), and performance score less than 2 correlated with superior survival but high Gal-1 expression significantly predicted adverse outcome at both univariate (HR 2.5, 95% CI, 1.1-5.7, P = .026) and multivariate levels (HR 3.2, 95% CI, 1.2-8.5, P = .017). Tumours with high Gal-1 had few cytotoxic T cells in the tumour microenvironment. High intratumoural Gal-1 expression before therapeutic intervention correlates with adverse outcome in nodal CD30+ , ALK- PTCL patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

59. TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma

Author

Loo, Suet K, Ch'ng, Ewe S, Md Salleh, Md Salzihan, Banham, Alison H, Pedersen, Lars M, Møller, Michael B, Green, Tina M, Wong, Kah K, Loo, Suet K, Ch'ng, Ewe S, Md Salleh, Md Salzihan, Banham, Alison H, Pedersen, Lars M, Møller, Michael B, Green, Tina M, and Wong, Kah K

Abstract

AIMS: Transient receptor potential channel melastatin 4 (TRPM4) is an ion channel that regulates influx of calcium cations (Ca2+). Recent studies suggest that TRPM4 is an oncoprotein, and its up-regulated transcript level has been reported in diffuse large B cell lymphoma (DLBCL). We aimed to investigate TRPM4 protein expression pattern in non-malignant tissues and DLBCL cases, and its association with clinico-demographic parameters and survival in DLBCL.METHODS AND RESULTS: Analysis of publicly available DLBCL microarray data sets showed that TRPM4 transcripts were up-regulated in DLBCL compared to normal germinal centre B (GCB) cells, were expressed more highly in the activated B cell-like DLBCL (ABC-DLBCL) subtype and higher TRPM4 transcripts conferred worse overall survival (OS) in R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)-treated DLBCL cases (P < 0.05). Our immunohistochemical analysis showed that TRPM4 was expressed in various human tissues but not in normal B cells within lymphoid tissues (reactive tonsil, lymph node and appendix). TRPM4 protein was present in 26% (n = 49 of 189) of our cohort of R-CHOP-treated DLBCL cases and this was associated significantly with more aggressive clinical parameters, including higher lactate dehydrogenase (LDH), Eastern Cooperative Oncology Group (ECOG) scores or stage (P < 0.01 for each of the parameters) and the ABC-DLBCL subtype (P = 0.016). TRPM4 positivity conferred significantly worse OS (P = 0.004) and progression-free survival (PFS) (P = 0.005). Worse OS remained associated significantly with TRPM4 positivity in multivariate analysis, including higher International Prognostic Index (IPI) or the non-GCB DLBCL phenotype (P < 0.05).CONCLUSIONS: TRPM4 protein expression is up-regulated in DLBCL cases compared to non-malignant B cells with preferential expression in ABC-DLBCL cases, and it confers significantly poorer DLBCL patient outcomes.

Published
2017

60. <html>Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma</html>

Author

Young, Ken H., Piris, Miguel A., Ferreri, Andrés J.M., van Krieken, J. Han, Huh, Jooryung, Ponzoni, Maurilio, Xu-Monette, Zijun Y., Zu, Youli, Hsi, Eric D., Richards, Kristy L., Jeffrey Medeiros, L., Møller, Michael B., Ok, Chi Young, Montes-Moreno, Santiago, Manyam, Ganiraju C., Chiu, April, Dybkaer, Karen, Tzankov, Alexandar, Wang, Jinfen, Parsons, Ben M., Visco, Carlo, Choi, William W.L., Winter, Jane N., Li, Ling, Pham, Lan V., Zhang, Mingzhi, Sun, Ruifang, Orazi, Attilio, and Bhagat, Govind

Subjects
animal structures, hemic and lymphatic diseases
Abstract

Dysregulated NF-κB signaling is critical for lymphomagenesis. The regulation, function, and clinical relevance of c-Rel/NF-κB activation in diffuse large B-cell lymphoma (DLBCL) have not been well studied. In this study we analyzed the prognostic significance and gene-expression signature of c-Rel nuclear expression as surrogate of c-Rel activation in 460 patients with de novo DLBCL. Nuclear c-Rel expression, observed in 137 (26.3%) DLBCL patients frequently associated with extranoal origin, did not show significantly prognostic impact in the overall- or germinal center B-like-DLBCL cohort, likely due to decreased pAKT and Myc levels, up-regulation of FOXP3, FOXO3, MEG3 and other tumor suppressors coincided with c-Rel nuclear expression, as well as the complicated relationships between NF-κB members and their overlapping function. However, c-Rel nuclear expression correlated with significantly poorer survival in p63+ and BCL-2− activated B-cell-like-DLBCL, and in DLBCL patients with TP53 mutations. Multivariate analysis indicated that after adjusting clinical parameters, c-Rel positivity was a significantly adverse prognostic factor in DLBCL patients with wild type TP53. Gene expression profiling suggested dysregulations of cell cycle, metabolism, adhesion, and migration associated with c-Rel activation. In contrast, REL amplification did not correlate with c-Rel nuclear expression and patient survival, likely due to co-amplification of genes that negatively regulate NF-κB activation. These insights into the expression, prognostic impact, regulation and function of c-Rel as well as its crosstalk with the p53 pathway underscore the importance of c-Rel and have significant therapeutic implications.

Published
2015
Full Text
View/download PDF

61. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary

Author

Richards, Kristy L., Zhang, Shanxiang, Ye, Qing, Orazi, Attilio, Zu, Youli, Abramson, Jeremy, Zhang, Li, Bhagat, Govind, van Krieken, J. Han, Xu-Monette, Zijun Y., Visco, Carlo, Ok, Chi Young, Wang, Xiaoxiao, Li, Ling, Hsi, Eric D., Deng, Lijuan, Tzankov, Alexandar, Goswami, Rashmi R., Chiu, April, Piris, Miguel A., Xu, Mina, Sohani, Aliyah R., Ponzoni, Maurilio, Winter, Jane N., Montes-Moreno, Santiago, Manyam, Ganiraju C., Choi, William W.L., Ferreri, Andrés J.M., Dybkaer, Karen, Huh, Jooryung, Møller, Michael B., and Parsons, Ben M.

Subjects
immune system diseases, hemic and lymphatic diseases, neoplasms
Abstract

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly (EBV+ DLBCL-e) is a molecularly distinct variant of DLBCL, characterized by a monoclonal B-cell proliferation that occurs in patients >50 years of age without a history or clinicopathologic evidence of immunodeficiency. However, patients with EBV+ DLBCL younger than 50-years-old also exist in Western countries. We evaluated the clinicopathologic, immunophenotypic and genetic features in Cacausian patients with EBV+ DLBCL who are ≤50 years of age and compared this patient group to patients who are >50 years. In patients who are ≤50 years, less frequent expression of BCL6 and a trend of more frequent expression of CD30 and pSTAT3 were found in patients with EBV+ DLBCL. In patients who are >50 years, common expression of CD30, p50, pSTAT3 and less frequent expression of BCL6 were observed. Older patients also more commonly had a poor performance status (ECOG≥2). Comparing EBV+ DLBCL patients in ≤50 years versus >50 years, both groups had similar clinicopathologic, immunophenotypic and genetic features. Gene expression profiling, microRNA profiling and treatment outcome of the younger patients with EBV+ DLBCL was not distinctive from tumors in older patients. Based on our data, we suggest that the arbitrary age cutoff for EBV+ DLBCL is unnecessary and should be eliminated in the WHO lymphoma classification scheme.

Published
2015
Full Text
View/download PDF

62. Proteomic Analysis Identifies Outcome-Predictive Clusters in Patients with Peripheral T-Cell Lymphoma, Not otherwise specified:Proteomic Analysis Identifies Outcome-Predictive Clusters in Patients with Peripheral T-Cell Lymphoma, Not otherwise specified

Author

Ludvigsen, Maja, Pedersen, Martin Bjerregård, Poulsen, T.S., Hamilton-Dutoit, Stephen Jacques, Besenbacher, Soren, Bendix, Knud, Møller, Michael B., D'Amore, Francesco Annibale, and Honoré, Bent

Subjects
hemic and lymphatic diseases
Abstract

Proteomic Analysis Identifies Outcome-Predictive Clusters in Patients with Peripheral T-Cell Lymphoma, Not otherwise specified

Published
2014

63. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy:A report from the International DLBCL Rituximab-CHOP Consortium Program

Author

Chi Young, Ok, Xu-Monette, Zijun Y, Tzankov, Alexandar, O'Malley, Dennis P, Montes-Moreno, Santiago, Visco, Carlo, Møller, Michael B, Dybkaer, Karen, Orazi, Attilio, Youli, Zu, Bhagat, Govind, Richards, Kristy L, Hsi, Eric D, Han van Krieken, J, Ponzoni, Maurilio, Farnen, John P, Piris, Miguel A, Winter, Jane N, Medeiros, L Jeffrey, and Young, Ken H

Subjects
Murine-Derived, Adult, Male, Lymphoma, diffuse large B-cell lymphoma, Lymphoma, Mantle-Cell, Antibodies, Disease-Free Survival, Antibodies, Monoclonal, Murine-Derived, Mice, Young Adult, immune system diseases, hemic and lymphatic diseases, Monoclonal, 80 and over, Large B-Cell, Prevalence, Animals, Humans, Cyclin D1, neoplasms, Cyclophosphamide, Aged, Aged, 80 and over, Daunorubicin, Mantle-Cell, Middle Aged, Prognosis, Diffuse, Immunohistochemistry, Vincristine, Prednisone, Female, Lymphoma, Large B-Cell, Diffuse, cyclin D1, pleomorphic mantle cell lymphoma, Rituximab
Abstract

BACKGROUND: Cyclin D1 expression has been reported in a subset of patients with diffuse large B-cell leukemia (DLBCL), but studies have been few and generally small, and they have demonstrated no obvious clinical implications attributable to cyclin D1 expression.METHODS: The authors reviewed 1435 patients who were diagnosed with DLBCL as part of the International DLBCL rituximab with cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (R-CHOP) Consortium Program and performed clinical, immunohistochemical, and genetic analyses with a focus on cyclin D1. All patients who were cyclin D1-positive according to immunohistochemistry were also assessed for rearrangements of the cyclin D1 gene (CCND1) using fluorescence in situ hybridization. Gene expression profiling was performed to compare patients who had DLBCL with and without cyclin D1 expression.RESULTS: In total, 30 patients (2.1%) who had DLBCL that expressed cyclin D1 and lacked CCND1 gene rearrangements were identified. Patients with cyclin D1-positive DLBCL had a median age of 57 years (range, 16.0-82.6 years). There were 23 males and 7 females. Twelve patients (40%) had bulky disease. None of them expressed CD5. Two patients expressed cyclin D2. Gene expression profiling indicated that 17 tumors were of the germinal center type, and 13 were of the activated B-cell type. Genetic aberrations of B-cell leukemia/lymphoma 2 (BCL2), BCL6, v-myc avian myelocytomatosis viral oncogene homolog (MYC), mouse double minute 2 oncogene E3 ubiquitin protein ligase (MDM2), MDM4, and tumor protein 53 (TP53) were rare or absent. Gene expression profiling did not reveal any striking differences with respect to cyclin D1 in DLBCL.CONCLUSIONS: Compared with patients who had cyclin D1-negative DLBCL, men were more commonly affected with cyclin D1-positive DLBCL, and they were significantly younger. There were no other significant differences in clinical presentation, pathologic features, overall survival, or progression-free survival between these two subgroups of patients with DLBCL. Cancer 2014;120:1818-1829. © 2014 American Cancer Society.

Published
2014
Full Text
View/download PDF

64. Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries

Author

Chi Young, Ok, Ling, Li, Xu-Monette, Zijun Y, Visco, Carlo, Tzankov, Alexander, Manyam, Ganiraju C, Montes-Moreno, Santiago, Dybkaer, Karen, Dybaer, Karen, Chiu, April, Orazi, Attilio, Youli, Zu, Bhagat, Govind, Chen, Jiayu, Richards, Kristy L, Hsi, Eric D, Choi, William W L, van Krieken, J Han, Huh, Jooryung, Weiyun, Ai, Ponzoni, Maurilio, Ferreri, Andrés J M, Farnen, John P, Møller, Michael B, Bueso-Ramos, Carlo E, Miranda, Roberto N, Winter, Jane N, Piris, Miguel A, Medeiros, L Jeffrey, Young, Ken H, Ok, Cy, Li, L, Xu Monette, Zy, Visco, C, Tzankov, A, Manyam, Gc, Montes Moreno, S, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Chen, J, Richards, Kl, Hsi, Ed, Choi, Ww, van Krieken, Jh, Huh, J, Ai, W, Ponzoni, Maurilio, Ferreri, Aj, Farnen, Jp, Møller, Mb, Bueso Ramos, Ce, Miranda, Rn, Winter, Jn, Piris, Ma, Medeiros, Lj, and Young, Kh

Subjects
Male, Cancer Research, Epstein-Barr Virus Infections, CD30, Lymphoma, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], CHOP, Antibodies, Monoclonal, Murine-Derived, immune system diseases, hemic and lymphatic diseases, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Prevalence, Cluster Analysis, Phosphorylation, Adult, Aged, Cyclophosphamide, Developed Countries, Doxorubicin, Female, Gene Expression Profiling, Humans, Ki-1 Antigen, Lymphoma, Large B-Cell, Diffuse, Middle Aged, NF-kappa B, Neoplasm Staging, Prednisone, Survival Analysis, Treatment Outcome, Tumor Burden, Vincristine, Diffuse, Oncology, Rituximab, medicine.drug, Murine-Derived, Biology, Article, Antibodies, medicine, Large B-Cell, Epstein–Barr virus infection, neoplasms, Survival analysis, Cancer, medicine.disease, Immunology, Cancer research, Diffuse large B-cell lymphoma
Abstract

Purpose: Epstein–Barr virus–positive (EBV+) diffuse large B-cell lymphoma (DLBCL) of the elderly is a variant of DLBCL with worse outcome that occurs most often in East-Asian countries and is uncommon in the Western hemisphere. We studied the largest cohort of EBV+ DLBCL, independent of age, treated with rituximab combined with CHOP (R-CHOP) in developed Western countries. Experimental design: A large cohort (n = 732) of patients with DLBCL treated with R-CHOP chemotherapy is included from the multicenter consortium. This study group has been studied for expression of different biomarkers by immunohistochemistry, genetic abnormalities by FISH and mutation analysis, genomic information by gene expression profiling (GEP), and gene set enrichment analysis (GSEA). Results: Twenty-eight patients (4.0%) were positive for EBV with a median age of 60.5 years. No clinical characteristics distinguished patients with EBV+ DLBCL from patients with EBV-negative (EBV−) DLBCL. Genetic aberrations were rarely seen. NF-κB p50, phosphorylated STAT-3, and CD30 were more commonly expressed in EBV+ DLBCLs (P < 0.05). Significant differences in survival were not observed in patients with EBV+ DLBCL versus EBV− DLBCL. However, CD30 expression combined with EBV conferred an inferior outcome. GEP showed a unique expression signature in EBV+ DLBCL. GSEA revealed enhanced activity of the NF-κB and JAK/STAT pathways independent of molecular subtype. Conclusions: The clinical characteristics of patients with EBV+ versus EBV− DLBCL are similar and EBV infection does not predict a worse outcome. EBV+ DLBCL, however, has a unique genetic signature. CD30 expression is more common in EBV+ DLBCL and, consistent CD30 and EBV is associated with an adverse outcome. Clin Cancer Res; 20(9); 2338–49. ©2014 AACR.

Published
2014
Full Text
View/download PDF

65. Multidisciplinary Management of Mastocytosis:Nordic Expert Group Consensus

Author

Broesby-Olsen, Sigurd, Dybedal, Ingunn, Gülen, Theo, Kristensen, Thomas, Møller, Michael B, Ackermann, Leena, Sääf, Maria, Karlsson, Maria A, Agertoft, Lone, Brixen, Kim, Hermann, Pernille, Stylianou, Eva, Mortz, Charlotte G, Torfing, Trine, Havelund, Troels, Sander, Birgitta, Bergström, Anna, Bendix, Marie, Garvey, Lene H, Bjerrum, Ole Weis, Valent, Peter, Bindslev-Jensen, Carsten, Nilsson, Gunnar, Vestergaard, Hanne, Hägglund, Hans, Broesby-Olsen, Sigurd, Dybedal, Ingunn, Gülen, Theo, Kristensen, Thomas, Møller, Michael B, Ackermann, Leena, Sääf, Maria, Karlsson, Maria A, Agertoft, Lone, Brixen, Kim, Hermann, Pernille, Stylianou, Eva, Mortz, Charlotte G, Torfing, Trine, Havelund, Troels, Sander, Birgitta, Bergström, Anna, Bendix, Marie, Garvey, Lene H, Bjerrum, Ole Weis, Valent, Peter, Bindslev-Jensen, Carsten, Nilsson, Gunnar, Vestergaard, Hanne, and Hägglund, Hans

Abstract

Mastocytosis is a heterogeneous group of diseases defined by an increased number and accumulation of mast cells, and often also by signs and symptoms of mast cell activation. Disease subtypes range from indolent to rare aggressive forms. Mastocytosis affects people of all ages and has been considered rare; however, it is probably underdiagnosed with potential severe implications. Diagnosis can be challenging and symptoms may be complex and involve multiple organ-systems. In general it is advised that patients should be referred to centres with experience in the disease offering an individualized, multidisciplinary approach. We present here consensus recommendations from a Nordic expert group for the diagnosis and general management of patients with mastocytosis.

Published
2016

66. Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP

Author

Green, Tina M., Jensen, Andreas K., Holst, René, Falgreen, Steffen, Bøgsted, Martin, de Stricker, Karin, Plesner, Torben, Mourits-Andersen, Torben, Frederiksen, Mikael, Johnsen, Hans E., Pedersen, Lars M., Møller, Michael B., Green, Tina M., Jensen, Andreas K., Holst, René, Falgreen, Steffen, Bøgsted, Martin, de Stricker, Karin, Plesner, Torben, Mourits-Andersen, Torben, Frederiksen, Mikael, Johnsen, Hans E., Pedersen, Lars M., and Møller, Michael B.

Abstract

We present a multiplex analysis for genes known to have prognostic value in an attempt to design a clinically useful classification model in patients with diffuse large B-cell lymphoma (DLBCL). Real-time polymerase chain reaction was used to measure transcript levels of 28 relevant genes in 194 de novo DLBCL patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Including International Prognostic Index (IPI) as a variable in a penalized Cox regression, we investigated the association with disease progression for single genes or gene combinations in four models. The best model was validated in data from an online available R-CHOP treated cohort. With progression-free survival (PFS) as primary endpoint, the best performing IPI independent model incorporated the LMO2 and HLADQA1 as well as gene interactions for GCSAMxMIB1, GCSAMxCTGF and FOXP1xPDE4B. This model assigned 33% of patients (n = 60) to poor outcome with an estimated 3-year PFS of 40% vs. 87% for low risk (n = 61) and intermediate (n = 60) risk groups (P < 0·001). However, a simpler, IPI independent model incorporated LMO2 and BCL2 and assigned 33% of the patients with a 3-year PFS of 35% vs. 82% for low risk group (P < 0·001). We have documented the impact of a few single genes added to IPI for assignment in new drug trials.

Published
2016

67. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma

Author

Zhang, Mingzhi, primary, Xu-Monette, Zijun Y., additional, Li, Ling, additional, Manyam, Ganiraju C., additional, Visco, Carlo, additional, Tzankov, Alexandar, additional, Wang, Jing, additional, Montes-Moreno, Santiago, additional, Dybkaer, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, Han van Krieken, J., additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Møller, Michael B., additional, Parsons, Ben M., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Medeiros, L. Jeffrey, additional, Pham, Lan V., additional, and Young, Ken H., additional

Published
2016
Full Text
View/download PDF

68. Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma

Author

Xu-Monette, Zijun Y., primary, Deng, Qipan, additional, Manyam, Ganiraju C., additional, Tzankov, Alexander, additional, Li, Ling, additional, Xia, Yi, additional, Wang, Xiao-xiao, additional, Zou, Dehui, additional, Visco, Carlo, additional, Dybkær, Karen, additional, Li, Jun, additional, Zhang, Li, additional, Liang, Han, additional, Montes-Moreno, Santiago, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, van Krieken, J. Han, additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Parsons, Ben M., additional, Møller, Michael B., additional, Wang, Sa A., additional, Miranda, Roberto N., additional, Piris, Miguel A., additional, Winter, Jane N., additional, Medeiros, L. Jeffrey, additional, Li, Yong, additional, and Young, Ken H., additional

Published
2016
Full Text
View/download PDF

70. Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP

Author

Green, Tina M., primary, Jensen, Andreas K., additional, Holst, René, additional, Falgreen, Steffen, additional, Bøgsted, Martin, additional, de Stricker, Karin, additional, Plesner, Torben, additional, Mourits-Andersen, Torben, additional, Frederiksen, Mikael, additional, Johnsen, Hans E., additional, Pedersen, Lars M., additional, and Møller, Michael B., additional

Published
2016
Full Text
View/download PDF

71. Phenotypic and Genotypic Profiling of MDM2, Respective to the TP53 Genetic Status, in Diffuse Large Bcell Lymphoma Patients Treated With Rituximab-CHOP Immunochemotherapy:A Report from the International DLBCL Rit

Author

Xu-Monette, Z Y, Møller, Michael B, Tzankov, A, Montes-Moreno, S, Hu, Wenwei, Manyam, Ganiraju C, Kristensen, Louise, Fan, Lei, Visco, Carlo, Dybkær, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Bhagat, G, Richards, Kristy L, Hsi, E D, Choi, William W.L., van Krieken, J H, Huang, Qin, Huh, Jooryung, Ai, Weiyun, Ponzoni, Maurilio, Ferreri, A J M, Wu, Lin, Winter, Jane N., Piris, M A, Medeiros, L J, and Young, Ken H

Published
2014

74. NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression*

Author

Kristensen, Thomas, Møller, Michael B, Friis, Lone, Bergmann, Olav J, and Preiss, Birgitte

Subjects
hemic and lymphatic diseases
Abstract

Mutation in the NPM1 gene occurs in 60% of acute myeloid leukaemia (AML) patients with normal karyotype. NPM1 mutation is potentially a superior minimal residual disease (MRD) marker compared to WT1 gene overexpression by being specific to the malignant clone, although experimental evidence published so far includes very limited numbers of relapsed cases. Also, the stability of the NPM1 mutation has been questioned by reports of the mutation being lost at relapse. In the present study we compared NPM1 mutation and WT1 overexpression as MRD markers in 20 cases of relapsed AML. The 20 patients experienced a total of 28 morphological relapses. Karyotypic evolution was detected in 56% of relapses. All relapses were accompanied by high levels of NPM1 mutation, along with high WT1 mRNA levels, thus demonstrating complete stability of both markers during relapse. Detectable NPM1 mutation following a period of morphological remission was accompanied by a morphological relapse in all cases. In contrast, WT1 expression was detected in 33% of the NPM1 mutation negative samples. This background WT1 expression produced by non-leukaemia cells was highly variable, both between and within patients, and limited the de facto sensitivity of the WT1 expression analysis. The present study therefore provides important experimental evidence demonstrating that NPM1 mutation is superior to WT1 overexpression as marker of MRD in NPM1-mutated AML, even in the presence of extensive karyotypic evolution.

Published
2011
Full Text
View/download PDF

75. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function

Author

Xu-Monette, Zijun Y., primary, Zhang, Shanxiang, additional, Li, Xin, additional, Manyam, Ganiraju C., additional, Wang, Xiao-xiao, additional, Xia, Yi, additional, Visco, Carlo, additional, Tzankov, Alexandar, additional, Zhang, Li, additional, Montes-Moreno, Santiago, additional, Dybkaer, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, van Krieken, J. Han, additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Zhao, Xiaoying, additional, Møller, Michael B., additional, Parsons, Ben M., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2016
Full Text
View/download PDF

76. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma

Author

Ye, Qing, primary, Xu-Monette, Zijun Y., additional, Tzankov, Alexandar, additional, Deng, Lijuan, additional, Wang, Xiaoxiao, additional, Manyam, Ganiraju C., additional, Visco, Carlo, additional, Montes-Moreno, Santiago, additional, Zhang, Li, additional, Dybkær, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, van Krieken, J. Han, additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Parsons, Ben M., additional, Møller, Michael B., additional, Piris, Miguel A., additional, Winter, Jane N., additional, Medeiros, L. Jeffrey, additional, Hu, Shimin, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

78. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma

Author

Li, Ling, primary, Xu-Monette, Zijun Y., additional, Ok, Chi Young, additional, Tzankov, Alexandar, additional, Manyam, Ganiraju C., additional, Sun, Ruifang, additional, Visco, Carlo, additional, Zhang, Mingzhi, additional, Montes-Moreno, Santiago, additional, Dybkaer, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, van Krieken, J. Han, additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Møller, Michael B., additional, Wang, Jinfen, additional, Parsons, Ben M., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Pham, Lan V., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

79. Nuclear coexpression of NF-κB subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium

Author

Li, Ling, primary, Xu-Monette, Zijun Y., additional, Ok, Chi Y., additional, Manyam, Ganiraju C., additional, Visco, Carlo, additional, Tzankov, Alexander, additional, Montes-Moreno, Santiago, additional, Dybkær, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, Han van Krieken, J., additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Farnen, John P., additional, Møller, Michael B., additional, Piris, Miguel A., additional, Winter, Jane N., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

80. Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program

Author

Liu, Zhiyu, primary, Xu-Monette, Zijun Y., additional, Cao, Xin, additional, Visco, Carlo, additional, Tzankov, Alexander, additional, Montes-Moreno, Santiago, additional, Dybkær, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, Han van Krieken, J., additional, Huh, Jooryung, additional, Ai, Weiyun, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Farnen, John P., additional, Møller, Michael B., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

81. Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program

Author

Shen, Qi, primary, Xu-Monette, Zijun Y., additional, Manyam, Ganiraju C., additional, Visco, Carlo, additional, Tzankov, Alexander, additional, Cao, Xin, additional, Deng, Lijuan, additional, Montes-Moreno, Santiago, additional, Dybkær, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, Han van Krieken, J., additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Farnen, John P., additional, Møller, Michael B., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

82. Clinical and Biological significance of MYC/BCL6 dual gene rearrangements and protein co-expression in de novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program

Author

Ye, Qinng, primary, Xu-Monette, Zijun Y., additional, Hu, Shimin, additional, Tzankov, Alexander, additional, Gisin, Nora, additional, Visco, Carlo, additional, Montes-Moreno, Santiago, additional, Dybkær, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, Han van Krieken, J., additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Møller, Michael B., additional, Go, Ronald S., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

83. MYC Signatures and Characterization of MYC-Driven Aggressive B-Cell Lymphoma

Author

Xu-Monette, Zijun Y., primary, Manyam, Ganiraju C., additional, Tzankov, Alexander, additional, Deng, Qipan, additional, Visco, Carlo, additional, Tu, Meifeng, additional, Li, Ling, additional, Zu, Youli, additional, Dybkaer, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, Han van Krieken, J., additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Møller, Michael B., additional, Farnen, John P., additional, Zhao, Xiaoying, additional, Piris, Miguel A., additional, Winter, Jane N., additional, Miranda, Roberto N., additional, McDonnell, Timothy J., additional, Medeiros, L. Jeffrey, additional, Li, Yong, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

84. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?

Author

Ok, Chi Young, primary, Ye, Qing, additional, Li, Ling, additional, Manyam, Ganiraju C., additional, Deng, Lijuan, additional, Goswami, Rashmi R., additional, Wang, Xiaoxiao, additional, Montes-Moreno, Santiago, additional, Visco, Carlo, additional, Tzankov, Alexandar, additional, Dybkaer, Karen, additional, Zhang, Li, additional, Abramson, Jeremy, additional, Sohani, Aliyah R., additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, van Krieken, J. Han, additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Zhang, Shanxiang, additional, Parsons, Ben M., additional, Xu, Mina, additional, Møller, Michael B., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Xu-Monette, Zijun Y., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

85. Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes With Prognosis

Author

Dybkær, Karen, primary, Bøgsted, Martin, additional, Falgreen, Steffen, additional, Bødker, Julie S., additional, Kjeldsen, Malene K., additional, Schmitz, Alexander, additional, Bilgrau, Anders E., additional, Xu-Monette, Zijun Y., additional, Li, Ling, additional, Bergkvist, Kim S., additional, Laursen, Maria B., additional, Rodrigo-Domingo, Maria, additional, Marques, Sara C., additional, Rasmussen, Sophie B., additional, Nyegaard, Mette, additional, Gaihede, Michael, additional, Møller, Michael B., additional, Samworth, Richard J., additional, Shah, Rajen D., additional, Johansen, Preben, additional, El-Galaly, Tarec C., additional, Young, Ken H., additional, and Johnsen, Hans E., additional

Published
2015
Full Text
View/download PDF

86. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries

Author

Xu-Monette, Zijun Y., primary, Tu, Meifeng, additional, Jabbar, Kausar J., additional, Cao, Xin, additional, Tzankov, Alexandar, additional, Visco, Carlo, additional, Cai, Qingqing, additional, Montes-Moreno, Santiago, additional, An, Yuji, additional, Dybkaer, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, van Krieken, J. Han, additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Zhao, Xiaoying, additional, Møller, Michael B., additional, Farnen, John P., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Miranda, Roberto N., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

87. Erratum: Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries

Author

Xu-Monette, Zijun Y., primary, Tu, Meifeng, additional, Jabbar, Kausar J., additional, Cao, Xin, additional, Tzankov, Alexandar, additional, Visco, Carlo, additional, Nagarajan, Lalitha, additional, Cai, Qinging, additional, Montes-Moreno, Santiago, additional, An, Yuji, additional, Dybkaer, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, van Krieken, J. Han, additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Zhao, Xiaoying, additional, Møller, Michael B., additional, Farnen, John P., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Miranda, Roberto N., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

89. A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry

Author

Gang, Anne O., primary, Pedersen, Michael, additional, d’Amore, Francesco, additional, Pedersen, Lars M., additional, Jensen, Bo A., additional, Jensen, Paw, additional, Møller, Michael B., additional, Mourits-Andersen, Hans T., additional, Pedersen, Robert S., additional, Klausen, Tobias W., additional, and de N. Brown, Peter, additional

Published
2015
Full Text
View/download PDF

90. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma

Author

Chen, Jiayu, primary, Xu-Monette, Zijun Y., additional, Deng, Lijuan, additional, Shen, Qi, additional, Manyam, Ganiraju C., additional, Martinez-Lopez, Azahara, additional, Zhang, Li, additional, Montes-Moreno, Santiago, additional, Visco, Carlo, additional, Tzankov, Alexandar, additional, Yin, Lihui, additional, Dybkaer, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, van Krieken, J. Han, additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Zhao, Xiaoying, additional, Møller, Michael B., additional, Farnen, John P., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Pham, Lan, additional, and Young, Ken H., additional

Published
2015
Full Text
View/download PDF

91. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases

Author

Møller, Michael B, Pedersen, Niels T, and Christensen, Bjarne E

Subjects
Adult, Aged, 80 and over, Male, Lymphoma, B-Cell, Adolescent, Denmark, Incidence, Middle Aged, Prognosis, Survival Rate, immune system diseases, hemic and lymphatic diseases, Humans, Female, Lymphoma, Large B-Cell, Diffuse, Prospective Studies, neoplasms, Aged
Abstract

Udgivelsesdato: 2004-Jan Differences in genetic origin between nodal and extranodal diffuse large B-cell lymphomas (DLBCL) exist. Using population-based data from the registry of the Danish Lymphoma Group, the present study is the first to analyse clinical implications of nodal versus extranodal presentation of DLBCL. Of 4786 newly diagnosed non-Hodgkin's lymphoma patients in a 16-year period, 1575 (33%) had DLBCL. The annual incidence rate was 2.9 per 100 000; 40% were extranodal. The clinical profile of patients with extranodal DLBCL was different from the nodal DLBCL patients. Extranodal DLBCL was associated with older age and poorer performance score, but also lower tumour burden. In extranodal DLBCL, 51% of the cases were stage I and 36% were stage IV, whereas the patients were relatively equally distributed between the four stages in nodal DLBCL. For stage I patients, extranodal DLBCL was independently associated with poor survival (P = 0.003). In contrast, among stage IV patients those with extranodal DLBCL survived longer (P = 0.009). We conclude that there are important clinical differences between nodal and extranodal DLBCL. The addition of these clinical results to the existing aetiological and genetic data suggests that the distinction between nodal and extranodal DLBCL is not only pathogenetically but also clinically important.

Published
2004

93. NF-κB Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program

Author

Li, Ling, primary, Xu-Monette, Zijun Yidan, additional, Ok, Chi Young, additional, Tzanko, Alexander, additional, Visco, Carlo, additional, Gisin, Nora, additional, Montes-Moreno, Santiago, additional, Dybkær, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W. L., additional, Van Krieken, Joannes H.J.M., additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andres J.M., additional, Møller, Michael B., additional, Go, Ronald S., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2014
Full Text
View/download PDF

94. Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program

Author

Shen, Qi, primary, Xu-Monette, Zijun Yidan, additional, Manyam, Ganiraju, additional, Visco, Carlo, additional, Tzankov, Alexander, additional, Cao, Xin, additional, Deng, Lijuan, additional, Montes-Moreno, Santiago, additional, Dybkær, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William, additional, Van Krieken, Joannes H.J.M., additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andres J.M., additional, Farnen, John P., additional, Møller, Michael B., additional, Winter, Jane N., additional, Piris, Miguel Angel A., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2014
Full Text
View/download PDF

95. A Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes with Prognosis

Author

Dybkær, Karen, primary, Bøgsted, Martin, additional, Falgreen, Steffen, additional, Kjeldsen, Malene Krag, additional, Schmitz, Alexander, additional, Bødker, Julie Støve, additional, Bilgrau, Anders Ellern, additional, Xu-Monette, Zijun Y., additional, Ling, Li, additional, Bergkvist, Kim Steve, additional, Laursen, Maria Bach, additional, Rodrigo-Domingo, Maria, additional, Marques, Sara Correia, additional, Rasmussen, Sophie Bech, additional, Nyegaard, Mette, additional, Gaihede, Michael, additional, Møller, Michael B., additional, Samworth, Richard, additional, Shah, Rajen, additional, Johansen, Preben, additional, El-Galaly, Tarec Christoffer, additional, Young, Ken H., additional, and Johnsen, Hans Erik, additional

Published
2014
Full Text
View/download PDF

96. Tumor Microenvironmental Features and Outcome in Post-Transplant Lymphoproliferative Disorder

Author

Vase, Maja Ølholm, primary, Maksten, Eva, additional, Bendix, Knud, additional, Hamilton-Dutoit, Stephen Jacques, additional, Andersen, Claus, additional, Møller, Michael B., additional, Sørensen, Søren Schwartz, additional, Jespersen, Bente, additional, Kampmann, Jan, additional, Rabinovich, Gabriel, additional, Søndergård, Esben, additional, Nielsen, Patricia Switten, additional, and d'Amore, Francesco, additional

Published
2014
Full Text
View/download PDF

98. Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma

Author

Ok, Chi Young, primary, Chen, Jiayu, additional, Xu-Monette, Zijun Y., additional, Tzankov, Alexandar, additional, Manyam, Ganiraju C., additional, Li, Ling, additional, Visco, Carlo, additional, Montes-Moreno, Santiago, additional, Dybkær, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, van Krieken, J. Han, additional, Huh, Jooryung, additional, Zhao, Xiaoying, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Bertoni, Francesco, additional, Farnen, John P., additional, Møller, Michael B., additional, Piris, Miguel A., additional, Winter, Jane N., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2014
Full Text
View/download PDF

99. Prevalence and Clinical Implications of Epstein-Barr Virus Infection in de novo Diffuse Large B-Cell Lymphoma in Western Countries: A report from The International DLBCL Rituximab-CHOP Consortium Program

Author

Ok, Chi Young, primary, Xu-Monette, Zijun Y., additional, Visco, Carlo, additional, Tzankov, Alexandar, additional, Montes-Moreno, Santiago, additional, Dybkær, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, van Krieken, J. Han, additional, Huh, Jooryung, additional, Ai, Weiyun, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Farnen, John P., additional, Møller, Michael B., additional, Bueso-Ramos, Carlo E., additional, Winter, Jane N., additional, Piris, Miguel A., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2014
Full Text
View/download PDF

100. Phenotypic and Genotypic Profiling of MDM2, Respective to the TP53 Genetic Status, in Diffuse Large B-cell Lymphoma Patients Treated With Rituximab-CHOP Immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program

Author

Xu-Monette, Zijun Y., primary, Møller, Michael B., additional, Tzankov, Alexander, additional, Montes-Moreno, Santiago, additional, Hu, Wenwei, additional, Manyam, Ganiraju C., additional, Kristensen, Louise, additional, Fan, Lei, additional, Visco, Carlo, additional, Dybkær, Karen, additional, Chiu, April, additional, Tam, Wayne, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W.L., additional, van Krieken, J. Han, additional, Huang, Qin, additional, Huh, Jooryung, additional, Ai, Weiyun, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Wu, Lin, additional, Zhao, Xiaoying, additional, Bueso-Ramos, Carlos E., additional, Wang, Sa A., additional, Go, Ronald S., additional, Li, Yong, additional, Winter, Jane N., additional, Piris, Miguel A., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results